Floatz logo

DOTATOC

Peripheral Primitive Neuroectodermal Tumor

ITM Solucin GmbHprotein_peptidePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Peripheral Primitive Neuroectodermal Tumor cohort.

Asset / SponsorPhaseRating
Palbociclib
National Cancer Institute (NCI)
Phase 2B
PI3K/MTOR INHIBITOR LY3023414
National Cancer Institute (NCI)
Phase 2B
Tazemetostat
National Cancer Institute (NCI)
Phase 2B
VEMURAFENIB
National Cancer Institute (NCI)
Phase 2CCC
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2CCC

View all 18 →

Same molecule, other indications

DOTATOC is also rated in:

digestive system neuroendocrine neoplasmDormant
B
Indicative ·
63 / 100
View asset →
neuroblastomaDormant
B
Indicative ·
60 / 100
View asset →
carcinoid tumorDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →